ArticleClinical and translational radiation oncology2026
VMAT-based lattice radiotherapy for advanced bulky hepatocellular carcinoma within multimodality treatment: a consecutive feasibility series.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bulky advanced hepatocellular carcinoma (HCC) remains difficult to treat with conventional homogeneous ablative radiotherapy because safe dose escalation is limited by hepatic reserve, tumor-to-liver geometry, and adjacent organs at risk (OARs). This study evaluated local control, tumor response, toxicity, and treatment continuity after volumetric-modulated arc therapy (VMAT)-based lattice radiotherapy (VMAT-LRT) in patients with advanced HCC. Methods: We retrospectively reviewed our initial consecutive VMAT-LRT cohort treated between October 2024 and March 2026. VMAT-LRT was considered for tumors >300 cm Results: Twelve VMAT-LRT courses in 11 patients were completed as planned. Median age was 70 years, median follow-up was 6.1 months, and median initial tumor volume was 557 cm Conclusion: VMAT-LRT was feasible for advanced bulky HCC, achieving meaningful tumor regression and durable in-field local control with acceptable toxicity while allowing continuation of multimodality treatment in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.